BioMap announced collaborations with 11 partners at the International Bio-Computing Innovation Summit 2026 in Hong Kong, extending its AI foundation-model work across drug research, traditional Chinese medicine, agricultural breeding and overseas expansion. The summit opened at the Hong Kong Convention and Exhibition Centre on November 6, 2026.
Seven projects were presented at the morning launch ceremony for BioMap InnoHub, followed by collaborations involving four additional organizations at an afternoon ceremony. BioMap hosted the event with support from Hong Kong Investment Corporation Limited. The collaborations are intended to advance AI research and applications in life sciences while accelerating the commercialization of research outcomes in Hong Kong.
Medical and Agricultural Projects
The University of Hong Kong collaboration advances the next phase of the Breast Cancer Virtual Cell Large Model project, using AI to simulate breast-cancer cell functioning and help researchers understand the disease. HKIC CEO Clara Chan said in her November 6 summit speech that the breast-cancer model’s phase II was launching in 2026, after an earlier multimodal breast-cancer tumor-cell foundation model was released at the 2025 summit.
Two other morning projects apply AI to different forms of therapeutic research. BioMap and Hong Kong Baptist University plan to establish an AI Traditional Chinese Medicine Joint Laboratory, combining computational analysis with experimental validation to investigate how traditional Chinese medicine ingredients work. A separate Novel Peptide Drug Incubation initiative with PepLib is intended to accelerate research and development of peptide and cyclic peptide therapeutics.
Agriculture received a parallel push. BioMap and Soy-Sky FarmTech will combine biological foundation models with crop genetic and trait data in an AI Breeding Platform designed to support breeding decisions. The partners also plan a Belt and Road AI Agricultural Innovation Ecosystem. Separately, BioMap will work with DEFTA Partners on the DEFTA Overseas Market Expansion Program, exploring research and industry collaboration in Japan and other overseas markets.
Shared Infrastructure and Regional Projects
Several collaborations concentrate on infrastructure connecting models with experiments. BioMap’s initiative with Coyote Bioscience combines research translation across industry, academia and research institutions with an open cartridge ecosystem, and supports collaboration on molecular point-of-care testing in Hong Kong. Its work with HiDream.ai on a Cross-Scale Virtual Organism Model will study biological phenomena at different scales and explore ways to predict and reconstruct their dynamics.
At the afternoon ceremony, BioMap said it would work with Temasek Life Sciences Laboratory on plans to jointly establish an AI Bio-Computing Center in Singapore. The center remains at the planning stage. Revvity is the partner for another planned facility: an AI biomanufacturing laboratory integrating computational and experimental workflows in a closed loop.
MegaStream Builds on a June Partnership
The afternoon program also featured MegaStream TechBio, the drug-development venture jointly established by BioMap and Harbour BioMed. CEO Kyler Lei made his first public appearance, outlined a drug-discovery vision called AIDD 3.0 and discussed a pipeline organized around First-in-Class and Best-in-Class programs. That presentation built on a partnership already disclosed earlier in the year: Harbour BioMed’s June 15, 2026 announcement said the companies would launch MegaStream as an AI-native pipeline company targeting global markets.
Under that plan, Harbour BioMed would contribute its fully human antibody platform, target-biology expertise and global clinical-development capabilities. BioMap would supply foundational AI technology, model engineering and intelligent research-and-development capabilities. MegaStream’s initial pipeline was to combine candidates identified by AI in the partners’ earlier collaborations with newly launched AI-driven discovery programs, prioritizing complex biologics across cardiovascular, renal, oncology and anti-aging areas.
The June release also described a planned dry-wet discovery laboratory linking computational design with experimental validation. Harbour BioMed projected efficiency gains above 500% over previous-generation platforms, a more than tenfold increase in data-accumulation efficiency and over 5 petabytes of AI-ready life-science data within five years. Those figures are operating targets for the planned laboratory, rather than performance results announced at the November summit.
For BioMap, the execution test is whether this expanding network can turn model predictions and automated experiments into validated therapies, breeding tools and commercial research outcomes across the regions covered by the summit partnerships.
Credit: Source link
